Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia
Mediterr J Hematol Infect Dis
.
2010 May 31;2(2):e2010012.
doi: 10.4084/MJHID.2010.012.
Authors
Alhossain Khalafallah
1
,
Terry Brain
Affiliation
1
Launceston General Hospital, Tasmania, Australia.
PMID:
21415965
PMCID:
PMC3033134
DOI:
10.4084/MJHID.2010.012
No abstract available